Esperion Therapeutics (NASDAQ:ESPR) Sets New 52-Week High – Here’s What Happened

Esperion Therapeutics, Inc. (NASDAQ:ESPR) shares reached a new 52-week high during mid-day trading on Monday . The company traded as high as $3.82 and last traded at $3.82, with a volume of 3018645 shares changing hands. The stock had previously closed at $3.48.

Analysts Set New Price Targets

A number of research firms have recently issued reports on ESPR. StockNews.com lowered shares of Esperion Therapeutics from a “buy” rating to a “hold” rating in a research note on Friday, November 15th. Needham & Company LLC dropped their price objective on shares of Esperion Therapeutics from $8.00 to $6.00 and set a “buy” rating on the stock in a research note on Tuesday, August 13th. Finally, HC Wainwright reiterated a “buy” rating and set a $16.00 price objective on shares of Esperion Therapeutics in a research note on Tuesday, December 3rd.

Esperion Therapeutics Stock Down 11.5 %

The business’s 50 day moving average is $2.36 and its 200-day moving average is $2.21. The firm has a market cap of $530.04 million, a P/E ratio of -4.02 and a beta of 1.01.

Institutional Trading of Esperion Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Wasatch Advisors LP boosted its holdings in Esperion Therapeutics by 38.4% in the third quarter. Wasatch Advisors LP now owns 23,346,013 shares of the biopharmaceutical company’s stock worth $38,521,000 after purchasing an additional 6,483,070 shares during the period. Geode Capital Management LLC increased its stake in Esperion Therapeutics by 4.1% during the third quarter. Geode Capital Management LLC now owns 4,331,314 shares of the biopharmaceutical company’s stock valued at $7,148,000 after purchasing an additional 171,609 shares during the last quarter. Marshall Wace LLP increased its stake in Esperion Therapeutics by 94.2% during the second quarter. Marshall Wace LLP now owns 4,303,596 shares of the biopharmaceutical company’s stock valued at $9,554,000 after purchasing an additional 2,087,635 shares during the last quarter. State Street Corp increased its stake in Esperion Therapeutics by 2.7% during the third quarter. State Street Corp now owns 3,854,314 shares of the biopharmaceutical company’s stock valued at $6,360,000 after purchasing an additional 99,802 shares during the last quarter. Finally, Connor Clark & Lunn Investment Management Ltd. increased its stake in Esperion Therapeutics by 71.0% during the third quarter. Connor Clark & Lunn Investment Management Ltd. now owns 711,278 shares of the biopharmaceutical company’s stock valued at $1,174,000 after purchasing an additional 295,378 shares during the last quarter. Institutional investors own 47.39% of the company’s stock.

Esperion Therapeutics Company Profile

Esperion Therapeutics, Inc, a pharmaceutical company, develops and commercializes medicines for the treatment of patients with elevated low density lipoprotein cholesterol (LDL-C). Its marketed products include NEXLETOL (bempedoic acid) and NEXLIZET (bempedoic acid and ezetimibe) tablets that are oral, once-daily, non-statin medicines for the treatment of primary hyperlipidemia in adults with heterozygous familial hypercholesterolemia or atherosclerotic cardiovascular disease who require additional lowering of LDL-C.